<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609659</url>
  </required_header>
  <id_info>
    <org_study_id>M15-582</org_study_id>
    <nct_id>NCT02609659</nct_id>
  </id_info>
  <brief_title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection</brief_title>
  <acronym>GEODE II</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the safety and efficacy of treatment with
      ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in non-cirrhotic, genotype 1a
      (GT1a) hepatitis C virus infected participants who are treatment-naïve or
      treatment-experienced with Interferon (IFN) or Pegylated Interferon (pegIFN) with or without
      Ribavirin (RBV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a 12-week Sustained Virologic Response (SVR12) Post-treatment</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Hemoglobin less than 10 g/dL</measure>
    <time_frame>Baseline (Day 1) and Treatment Weeks 2, 4, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of participants with hemoglobin less than 10 g/dL during treatment and decreased from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with On-treatment Virologic Failure.</measure>
    <time_frame>Up to 12 weeks while on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-treatment virologic failure is defined as confirmed 1 log10 IU/mL increase from nadir in HCV RNA at any time point during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Post-treatment Relapse</measure>
    <time_frame>Between end of treatment (Week 12) and post-treatment (up to Week 24 post-treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Relapse is defined as confirmed HCV RNA greater than or equal to the LLOQ between end of treatment and 12 weeks after last dose of study drug (up to and including the SVR12 assessment time point) among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir plus Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) + Ribavirin (600 mg QD) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>Tablet; Ombitasvir co-formulated with Paritaprevir and Ritonavir</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir plus Ribavirin</arm_group_label>
    <other_name>ABT-267/ABT-450/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir plus Ribavirin</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir plus Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV infection

          -  Non-cirrhotic subjects

          -  Screening laboratory results showing HCV Genotype 1a infection

          -  HCV treatment-naïve or if treated previously, only with IFN or pegINF with or without
             RBV

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus
             antibody (HIV Ab)

          -  HCV genotype of any subtype other than 1a or unable to subtype

          -  Prior or current use of any investigational or commercially available anti-HCV agents
             other than IFN, pegIFN or RBV. Subjects with previous participation in trials of
             investigational direct-acting antiviral agents (DAAs) may be enrolled if they can
             produce documentation that they received only placebo.

          -  Current enrollment in another interventional clinical study or receipt of any
             investigational product within 6 weeks prior to study drug administration.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisol Martinez, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Glowinski, BA</last_name>
    <phone>847-937-4263</phone>
    <email>paula.glowinski@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Oliver, BS</last_name>
    <phone>847-938-5570</phone>
    <email>brian.oliver@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144661</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144661, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144667</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144667, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144659</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144659, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144665</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144665, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144655</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144655, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144656</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144656, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144666</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144666, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144664</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144664, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144660</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144660, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 18, 2015</lastchanged_date>
  <firstreceived_date>November 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Infection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
